NCT07346404Not yet recruitingPhase 2
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study. is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Kidney cancer
- NCT number
- NCT07346404
- EU CT number
- 2024-514085-39-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 1 Jan 2026 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
Other
- Pregnant or breastfeeding women
- Patient under legal protection (guardianship)
- Contraindication to the PET-CT
- Contraindication to the injection of 82-Rb
- Patient on SMA (state medical aid)
- Unilateral renal agenesis
- Multicystic renal dysplasia
- Hereditary forms of RCC as VHL, MET, FH and FLCN
- Bosniak 3 cysts
- Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
- Exclusion of clear renal cell adenocarcinoma on biopsy
- Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).
Who the study is looking for
- Age ≥ 18 years old
- Signed written informed consent
- French Social Security affiliation
- Patients with high suspicion of or confirmed RCC requiring surgical resection
- Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique Hopitaux de Paris Coordinator of this site? Confirm its status | Paris | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.